| 发明名称 | Ceftolozane-tazobactam pharmaceutical compositions | ||
| 摘要 | Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam. | ||
| 申请公布号 | US8968753(B2) | 申请公布日期 | 2015.03.03 |
| 申请号 | US201414285185 | 申请日期 | 2014.05.22 |
| 申请人 | Calixa Therapeutics, Inc. | 发明人 | Terracciano Joseph;Damour Nicole Miller;Jiang Chun;Fogliato Giovanni;Donadelli Giuseppe Alessandro;Resemini Dario |
| 分类号 | A61K9/00;A61K31/43;A61K31/545;A61K9/19;A61K31/546;A61K31/431;A61K47/02;A61K47/12;A61K47/18 | 主分类号 | A61K9/00 |
| 代理机构 | Lathrop & Gage LLP | 代理人 | Lathrop & Gage LLP ;Trinque Brian C. |
| 主权项 | 1. A method of treating an infection selected from the group consisting of a complicated intra-abdominal infection and a complicated urinary tract infection in a patient comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising (a) ceftolozane lyophilized in the absence of tazobactam and (b) a tazobactam composition, in a ratio of 1,000 mg ceftolozane active per 500 mg of tazobactam active. | ||
| 地址 | Lexington MA US | ||